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Abstract
Stored neonatal dried blood spot (DBS) samples from neonatal screening programmes are
a valuable diagnostic and research resource. Combined with information from national
health registries they can be used in population-based studies of genetic diseases. DNA
extracted from neonatal DBSs can be amplified to obtain micrograms of an otherwise limited
resource, referred to as whole-genome amplified DNA (wgaDNA). Here we investigate the
robustness of exome sequencing of wgaDNA of neonatal DBS samples. We conducted
three pilot studies of seven, eight and seven subjects, respectively. For each subject we
analysed a neonatal DBS sample and corresponding adult whole-blood (WB) reference
sample. Different DNA sample types were prepared for each of the subjects. Pilot 1:
wgaDNA of 2x3.2mm neonatal DBSs (DBS_2x3.2) and raw DNA extract of the WB refer-
ence sample (WB_ref). Pilot 2: DBS_2x3.2, WB_ref and aWB_ref replica sharing DNA
extract with the WB_ref sample. Pilot 3: DBS_2x3.2, WB_ref, wgaDNA of 2x1.6 mm neona-
tal DBSs and wgaDNA of the WB reference sample. Following sequencing and data analy-
sis, we compared pairwise variant calls to obtain a measure of similarity—the concordance
rate. Concordance rates were slightly lower when comparing DBS vs WB sample types
than for any two WB sample types of the same subject before filtering of the variant calls.
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The overall concordance rates were dependent on the variant type, with SNPs performing
best. Post-filtering, the comparisons of DBS vs WB andWB vsWB sample types yielded
similar concordance rates, with values close to 100%. WgaDNA of neonatal DBS samples
performs with great accuracy and efficiency in exome sequencing. The wgaDNA performed
similarly to matched high-quality reference—whole-blood DNA—based on concordance
rates calculated from variant calls. No differences were observed substituting 2x3.2 with
2x1.6 mm discs, allowing for additional reduction of sample material in future projects.
Introduction
The accurate genotyping of DNA of neonatal dried blood spot (DBS) samples has proven plau-
sible, and opened new avenues in neonatal screening and for identification of determinants in
complex genetic diseases [1, 2]. Several countries store the excess neonatal DBS samples in
repositories known as biobanks, but in only a few of the cases the samples are stored at frost,
including Denmark in which storage is at -20°C [3–8]. Frost storage generally serves to pre-
serve the overall sample quality compared to samples stored at room temperature, which will
be more restricted in their use. Combined with the relevant clinical information, the neonatal
DBS samples can be used for genome-wide association studies of disease to provide for the nec-
essary cohort size [9].
In Denmark neonatal DBS samples are stored in the Danish Neonatal Screening Biobank
(DNSB), which today contains over two million samples representing close to 100% of the
Danes born after 1982 [8, 10]. At birth, Danish citizens are assigned a unique person-identify-
ing number used across all public registration systems including the DNSB and in the well-
established public health care system. This makes it possible to study the entire population
under a certain age as a single cohort, and consequently to identify the determinants of com-
mon and complex genetic diseases in the Caucasian ethnicity [11]. The use of neonatal DBS
samples for such ventures is however, challenged by the very small amount of blood available
with three spots of ~50 μl blood per sample being collected for neonatal screening. The major-
ity of surplus material is often also reserved for other purposes, including in order of priority:
analysis for the benefit of the child and family, development and optimization of the current
screening programme and research projects [9]. Most projects are therefore limited to a maxi-
mum of two discs of 3.2 mm size per sample with each spot yielding a maximum of 60 ng of
retrievable DNA [12]. This restricts the use of neonatal DBS samples to a limited set of technol-
ogies/platforms, most often with no possibility of repeating the experiments. For genetic stud-
ies this may be overcome by whole-genome amplification (WGA) of the DNA (wgaDNA)
leading to microgram quantities [13]. The genotyping accuracy of neonatal wgaDNA has previ-
ously been questioned. However, several studies have shown that the wgaDNA performs
equally well compared to high-quality DNA of other sources, using low- and high-throughput
genotyping platforms [1, 14, 15]: the wgaDNA has been used with great success in research
projects looking at infantile hypertrophic pyloric stenosis [16], birth weight [17], schizophrenia
[18, 19], psychosis [20] and cerebral palsy [21]. We recently found that the wgaDNA also
works for next-generation sequencing (NGS) [22]: an adult whole-blood (WB) reference sam-
ple (WB_ref), a three-year old DBS reference sample of the same person and the corresponding
archived neonatal DBS sample were compared. The reference DBS and neonatal DBS samples
were WGA following DNA extraction, which was not the case for the WB_ref. The data were
of high quality containing similar SNP error rates for all sample types inspected, no matter the
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approach taken. However, as this study only included two subjects, the robustness’s of the
methodology still needs to be confirmed.
This paper forms a continuation of the work done in Hollegaard et al. [22], where we seek
to establish and expand the feasibility of using neonatal DBS samples for exome-targeted next-
generation sequencing (WES). We aim to show that WGA is robust and reproducible; indepen-
dent of kit and sequencing site. Thus, three different library preparation kits and two different
sequencing sites were used for this study. The cohort size is expanded to include 22 subjects
matched by a neonatal DBS sample and adult WB reference sample each. The study uses a
comparison of replicated WB samples to establish a base-line of technical reproducibility, any
variance beyond that of the WB replicas is inferred to be due to the WGA. The compatibility of
using smaller inputs of neonatal DBSs (i.e. smaller disc size) with the sequencing technology is
also investigated. This could provide for greater flexibility in future project designs and/or for
neonatal screening. The relative sample performance is inferred from a similarity measure—
the concordance rate—representing a pairwise comparison of genotypes calls at the variant
sites. This allows us to compare the DBS-derived wgaDNA with high-quality DNA of aWB ref-
erence sample, to provide the final call of sample performance.
Methods
Study Design and Samples
This study represents a compilation of three separate pilot studies: Pilot 1, Pilot 2 and Pilot 3
containing seven, eight and seven subjects, respectively. We used a neonatal DBS sample and a
corresponding adult WB reference sample for each individual, which were retrieved from the
DNSB [23]. As defined by the 'Danish Act on Research Ethics Review of Health Research Proj-
ects' Section 2, this project does not constitute a health research project but is considered a
quality developmental project for neonatal screening—thus it can be conducted without
approval from the Committees on Biomedical Research Ethics for the Capital Region of
Denmark.
Fig 1 provides a detailed overview of the study design and sample preparation used in the
respective pilots. Note that all details of sample preparation relevant to differentiate between
DNA sample types are described herein. The sample types prepared were for Pilot 1:
DBS_2×3.2 and WB_ref sample types; Pilot 2: DBS_2×3.2, WB_ref and WB_ref_replica sam-
ple types and Pilot 3: DBS_2×1.6, DBS_2×3.2, WB_WGA_ref and corresponding WB_ ref
sample types. DNA extractions of the WB reference samples were with the Maxwell 16 LEV
Blood DNA Kit (Promega) as prescribed by the manufacturer, and DNA extractions of the
neonatal DBS samples were with the Extract-N-Amp Blood PCR Kit (Sigma) as described
previously [1]. WGA was carried out in triplicate using the REPLIg Kit (QIAGEN) as has
also been described previously [1]. The DNA was quantified using the Quant-IT PicoGreen
dsDNA Reagent (Invitrogen) before library preparation and sequencing.
Sequencing and Library Preparation
Library preparation and sequencing of the samples in Pilot 1 and Pilot 2 were performed at
BGI-Europe, Copenhagen, Denmark—and those of Pilot 3 at Broad Institute's Genomics Plat-
form, Cambridge, USA. The total number of samples processed were in Pilot 1: 14 (7 subjects
of DBS_2x3.2 and WB_ref sample types), Pilot 2: 24 (8 subjects of DBS_2x3.2, WB_ref and
WB_ref replica sample types) and Pilot 3: 42 (7 subjects of DBS_2x3.2, DBS_2x1.6 (prepared
in triplicate), WB_ref and WB_WGA_ref sample types). Different library preparation kits were
used in the pilots. Pilot 1: SureSelectXT Human All Exon V4 kit (Agilent), Pilot 2: a BGI Cap-
ture kit (produced in-house at BGI) and Pilot 3: SureSelectXT Human All Exon V2 kit
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(Agilent). The libraries of Pilot 1 and Pilot 3 were prepared according to the manufacturers
instructions using 1 μg of input DNA per sample. Library preparation in Pilot 2 were with 500
ng of DNA as input per sample. Library validation was with the KAPA Library Quantification
Kit (KAPA Biosystems), and sequencing was performed on a HiSeq2000 Sequencer for the
samples of Pilot 1 and Pilot 2 and a HiSeq2500 Sequencer for the samples of Pilot 3.
Data Analysis
Mapping. The sample reads were aligned to the genome (reference GRCh37) using BWA
version 0.7.4, converted to BAM format and indexed using SAMtools (version 0.1.18). The
samples were re-aligned, marked for duplicates and recalibrated using GATK and Queue (ver-
sion 2.7–2) as pipeline manager.
Variant Calling: the variants were called using HaplotypeCaller and UnifiedGenotyper, pro-
cessed with VQSR following the best practices for the version in use, and pre-filtered by 'PASS'
Fig 1. Study design. This study aims to identify systematic differences between DBS andWB by testing
both sample types from a number of individuals. Pilot 1, Pilot 2 and Pilot 3 included seven, eight and seven
subjects represented with a neonatal DBS sample and corresponding adult WB reference sample each,
respectively. A minimum of two sample types per subject were prepared for library preparation: wgaDNA of
DNA from 2x3.2 mm of neonatal DBSs (DBS_2×3.2) and raw control DNA from theWB reference sample
(WB_ref). Pilot 2 also included a replicate sample of each of the WB_ref samples (WB_ref_replicate)
(replicate sample not shown in the cartoon). Pilot 3 included two additional sample types; WGA of DNA from
2x1.6 mm neonatal DBS (DBS_2x1.6) andWGA of theWB reference sample (WB_WGA_ref). Note that the
DBS_2x1.6 sample type of Pilot 3 was prepared and sequenced in triplicate using different sets of 2x1.6 mm
discs for all of the subjects included. The samples were set up for library preparation using different kits in the
respective pilot studies, before sequencing and data analysis. Please note the color-coding used with green,
blue and orange specifying the respective pilot studies. All samples were retrieved from the Danish Neonatal
Screening Biobank.
doi:10.1371/journal.pone.0153253.g001
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at the output of each caller. The calls were merged by including, in order of priority: All 'PASS'
HaplotypeCaller variants and All 'PASS' calls unique to UnifiedGenotyper. This implies that i)
in case of overlapping 'PASS' variants, the calls from HaplotypeCaller were included, ii) in case
of overlapping variants filtered by VQSR in HaplotypeCaller and 'PASS' in UnifiedGenotyper,
the UnifiedGenotyper calls were included and iii) all 'PASS' non-overlapping variants unique
to each caller were included.
Annotation. The variants were annotated using the snpEFF (version 3.3h), EPACTS
(version 3.3) and Variant Effect Predictor (version 75) tools from ENSEMBL, and the variant
type using the GATK VariantAnnotator. Based on this, the variant calls were grouped into
SNPs, insertions, deletions and multiallelelic calls. The group of multiallelic calls comprises
the variant types identified by GATK as 'MULTIALLELIC_COMPLEX.Other' and 'MULTIAL
LELIC_MIXED': the first includes the variants represented by multiple alleles containing
insertions or deletions (or a combination hereof) of different sizes, while the second includes
the variants in which multiple alternative alleles can be a combination of SNPs, insertions
and/or deletions.
Filtering: both a variant-level approach (depth) and a sample-level approach (genotype
quality) were employed for filtering of the variant calls: we set a threshold for the average sam-
ple depth>20 and for the minimum genotype quality (minGQ) across the WB_ref samples
(minGQ_WB)>30. The average sample depth was calculated by dividing the multi sample
depth with the number of samples included in the respective callings. The minGQ_WB criteria
only considers the variant calls of the WB_ref samples using this as the high-quality standard.
In case of missing data, the minGQ_WB value was set to 0.
Concordance. Sample performance was evaluated based on a pairwise comparison of
genotypes (the variant calls) resulting in a similarity measure between any two samples—the
concordance rate. Similarity measures were categorized in five groups as: concordant–for iden-
tical genotypes between samples the calls being either present or missing, discordant (het/
homo)–for genotype calls differing between samples one call being homozygous (for the refer-
ence or for the first alternative allele) and the other heterozygous (reference, or first alternative
allele), discordant (homo/homo)—for genotype calls differing between samples one being
homozygous for the reference and the other homozygous for the first alternative allele, discor-
dant (other)—for genotype calls differing between samples and which involve alternative alleles
other than the first,missing–for genotypes exhibiting 'no call' in only one of the two samples.
Here only the concordance rate has been used to highlight the key element of our performance
comparisons: probing the relative similarity of wgaDNA of neonatal DBS samples to high-
quality DNA of WB samples obtained from the same subjects. We have compared the paired
samples, i.e. originating from the same subject of the DBS_2x3.2 and WB_ref sample types in
all pilots (comparisons will henceforth be denoted as [sample type 1] vs [sample type 2]). In
Pilot 2, we also compared the WB_ref and WB_ref replica sample types for comparison to the
DBS_2x3.2 vs WB_ref comparisons. Additional comparisons made for Pilot 3 were DBS_2x1.6
vs WB_ref, DBS_2x3.2 vs DBS_2x1.6 andWB_ref vs WB_WGA_ref, respectively.
Results and Discussion
WES Statistics—Coverage
Defining the required coverage is a subjective matter much depending on species, type of sam-
ple and scope of study. At a given site in a diploid genome, a depth threshold of 30X can be
considered sufficient for calling high-quality variants. Defining this as our minimum threshold,
we analysed the proportion of target regions in our data, displaying an average depth above
30X in each of the sample types (Fig 2). The statistics reveal a clear-cut difference in percentage
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of sequences reaching the standard threshold of 30X between the DBS and corresponding WB
samples with the former exhibiting reduced threshold coverage. For the DBS_2x3.2 and
WB_ref sample types, this difference was ~10.7% in Pilot 1, ~5.9% in Pilot 2 and ~6.9% in Pilot
3. Despite hereof, the results are still in an acceptable range for the DBS samples (between
~60–75% of exome coverage>30X) as compared with other samples for which high-quality
WES data have been obtained [24, 25]. We also calculated the medians of percentage of exome
coverage at depth>10X. For Pilot 1 this was 94.9% and 97.6% for the DBS_2x3.2 andWB_ref
sample types, respectively. Pilot 2: 86.9%, 93.7% and 94.1% for the DBS_2x3.2, WB_ref and
WB_ref_replica sample types, respectively. Pilot 3: 88.8%, 87.9%, 92.5% and 92.1% for the
DBS_2x1.6, DBS_2x3.2, WB_WGA_ref and WB_ref sample types, respectively. At>10X, a
reduced threshold coverage of ~2.7% in Pilot 1, ~6.8% in Pilot 2 and ~4.2% in Pilot 3 existed
for the DBS_2x3.2 sample type as compared to the WB_ref sample type. We found no differ-
ences between the DBS_2x3.2 and DBS_2x1.6 sample types of Pilot 3, suggesting that coverage
is independent of disc size in the range tested. In Pilot 3 in particular, the analyses have been
run in triplicates, allowing us to perform a technical replication and verify the absence of ran-
dom bias. We have not conducted further investigation into why the coverage is apparently
Fig 2. Exome coverage by depth. The data were presented with a box plot as percentage of exome
coverage with sequencing depths greater than 30. The exact medians of the observations have been listed
above the plot. From left to right, the pilots were depicted in the order: Pilot 1 with DBS_2x3.2 andWB_ref
sample types, Pilot 2 with DBS_2x3.2, WB_ref andWB_ref replica sample types and Pilot 3 with DBS_2x1.6,
DBS_2x3.2, WB_WGA_ref andWB_ref sample types, respectively. In the plot, the medians are given by a
solid black line enclosed in boxes specifying the first and third quartiles. The whiskers represent the statistical
dispersion of the data using the interquartile range (1.5*IQR). Data beyond 1.5*IQR range are outliers and
plotted as dots. Note that the number of observations per sample type (not considering DBS_2x1.6, see
below) equals the number of subjects included in the pilot, i.e. Pilot 1 = 7, Pilot 2 = 8 and Pilot 3 = 7. The
DBS_2x1.6 sample type was plotted using all 21 observations, resulting from the triplicate experiments per
subject of different sets of 2x1.6 mm discs included in Pilot 3. The coverage statistics were calculated with
GATK using R to obtain the percentage of exome coverage per sample type shown.
doi:10.1371/journal.pone.0153253.g002
High-Quality Exome Sequencing of Whole-Genome Amplified Neonatal Dried Blood Spot DNA
PLOSONE | DOI:10.1371/journal.pone.0153253 April 18, 2016 6 / 13
reduced in WGA samples. Duplicate reads percentages was found to depend more on kit than
on whether amplification was used. Respectively for pilot one/two/three Duplication rates for
WB were 18%/9%/14%, for DBS they were 18%/9%/16%. The scope of this study was to investi-
gate whether confidently discovered variant were reliable, we leave it to future studies to eluci-
date if genomic regions are lost. We conclude that the data quality is of a reasonable standard
to proceed onwards launching the subsequent steps of variant calling.
Variant Calling and Filtering
The variants were called by a multi-sample approach on a per-pilot basis, resulting in a single
variant number count for each of the pilots. Variant calling was performed with merged Haplo-
typeCaller and UnifiedGenotyper calls as described in the methods section. In order to assess
the performance of neonatal DBS samples as compared to WB samples, we needed to introduce
a variant filter to remove the variability in genotype calling resulting from other factors, most
commonly sequence quality. The multi-sample calling approach was chosen in order to focus
our attention on the genotype call (i.e. the accuracy) rather than the emission variant site. In
this way, while improving the calling of sites where a variant is present, we could identify spe-
cifically which parameters differentiate those loci where different genotypes (discordant) have
been called. We thus explored the distribution of the parameters used by GATK Variant Qual-
ity Score Recalibration and found that discordant variants between sample types accumulated
either at low sequencing depths (<20) or as variants exhibiting low call quality scores. Besides
common genomic characteristics (variant-level filters) we also wanted to highlight characteris-
tics of the samples, which might be responsible for discordant calls (sample-level filters).
Therefore we adopted two criteria for the filtering: i) a variant-level filter on a generally recog-
nised minimum threshold of sequence reliability, i.e. average sample depth>20 and ii) a sam-
ple-level filter summarising several sample-specific quality parameters, i.e. minimum genotype
quality calculated only across WB_ref samples (minGQ_WB)>30. The first criterion func-
tioned to remove the variants in areas covered by less than 20 reads (on average), and the sec-
ond removed the variants of the WB_ref samples exhibiting genotype scores less than or equal
to 30, while keeping those of high quality (>30) no matter the score of the corresponding vari-
ants in the other sample types. The variants were annotated for partitioning into SNPs, inser-
tions, deletions and multiallelic calls, respectively. A summary of the variant calls before and
after filtering is available in S1 Table. The calls were found to group by decreasing frequency of
observation as SNPs> insertions> deletions>multiallelic calls with SNPs being greatly over-
represented in all pilots as well before as after filtering of the variants (84–94% of all variant
calls are an SNP). As expected, the total number of variants varies depending on the capture
strategy employed, which most likely result from actual differences in the genomic regions tar-
geted including repetitive regions outside the exome. We subsequently used the variant calls
for a more comprehensive comparison of sample types.
Evaluation of Sample Performance by Pairwise Comparison of
Genotypes—Concordance Rates
To evaluate sample performance we executed a pairwise comparison of genotypes based on the
variant calls resulting in a similarity measure between different sample types—the concordance
rate (Fig 3). Concordance rates were obtained both before and after filtering of the calls and
grouped by variant type into SNPs, insertions, deletions and multiallelic calls. The numbers
supporting the graphs in Fig 3 are available in table format in S2 Table. We compared the
DBS_2x3.2 andWB_ref sample types (all pilots) to obtain a measure of the feasibility of
sequencing neonatal DBS samples. The WB_ref and WB_ref replica sample types of Pilot 2
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were compared to establish a high-quality standard used for comparison to the DBS_2x3.2 vs
WB_ref comparison, thereby testing the relative performance of the DBS_2x3.2 sample type.
The DBS_2x1.6 vs WB_ref and DBS_2x3.2 vs DBS_2x1.6 comparisons of Pilot 3 were made in
order to evaluate the potential of reducing the disc size, and the WB_ref vs WB_WGA_ref
comparison for probing an effect resulting from the amplification reaction. A comparison of
the DBS_2x1.6 sample type replicas with the WB_ref sample type, i.e. replica_1 vs WB_ref,
replica_2 vs WB_ref and replica_3 vs WB_ref yielded similar concordance rates (see S1 Fig).
Based on this, we decided to include all of the data of the DBS_2x1.6 sample type for calcula-
tion of the concordances displayed in Fig 3; that is the DBS_2x1.6 vs WB_ref and DBS_2x3.2
vs DBS_2x1.6 comparisons, respectively. This was done by initial comparison of each of the
DBS_2x1.6 sample type replicas with the WB_ref or DBS_2x3.2 sample types, followed by the
calculation of average values hereof. An initial look at the concordances in Fig 3 before filtering
show strong dependency by variant type with SNPs> insertions> deletions>mulitiallelic
calls, respectively (upper panels). This is similar to what has previously been observed in WES
studies splitting calls by variant type, and results due to well-known difficulties of calling high-
complexity variants as well as a general higher probability of encountering sequence variation
Fig 3. Comparison of sample types from variant calls—concordance rates. The concordance rates
were calculated by pairwise comparison of variant calls before (upper panels) and after filtering (lower
panels). The sample types compared were DBS_2x3.2 vs WB_ref in Pilot 1 (A and B), DBS_2x3.2 vs WB_ref
andWB_ref vs WB_ref replica in Pilot 2 (C and D) and DBS_2x1.6 vsWB_ref, DBS_2x3.2 vs WB_ref,
DBS_2x3.2 vs DBS_2x1.6 andWB_ref vs WB_WGA_ref in Pilot 3 (E and F). The rates have been presented
per variant type: SNP, insertion, deletion and multiallelic calls, and comprise the averages of all comparisons
made for a given sample pair, corresponding to the number of subjects in the pilot, i.e. Pilot 1 = 7, Pilot 2 = 8
and Pilot 3 = 7. Note that for comparisons using the DBS_2x1.6 sample type (see the fig), each individual
replica was firstly compared to theWB_ref or DBS_2x3.2 sample types followed by the calculation of average
values hereof, which were used in the figure.
doi:10.1371/journal.pone.0153253.g003
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between any two samples for variants of increasing lengths [26]. The pre-filtered concordance
rates are consistent with other exome sequencing experiments dealing with sample replicas:
previous reported rates were in the range of 82–92%, the numbers being largely dependent on
the depth of coverage, as is also reported here [27]. Notably, we observe somewhat lower con-
cordance rates of the DBS vs WB comparisons (i.e. all comparisons of neonatal DBS samples
andWB reference samples) over the WB vs WB comparisons (all comparisons of WB reference
samples) before filtering in Pilot 2 and Pilot 3, which may be ascribed to subtle differences in
overall DNA quality of DBS-derived wgaDNA as compared to WB-derived DNA. This differ-
ence become neutralized after filtering yielding similar concordance rates between the DBS vs
WB andWB vs WB comparisons independent of whether 2x3.2 mm or 2x1.6 mm discs were
used for DNA extraction. Moreover, post-filtering the concordance rates of all pairwise com-
pared samples are very close to 100% (the multiallelic calls of Pilots 1 and 3 omitted, for which
rates only reaches 85–88%). This shows that DBS-derived wgaDNA no matter the input quan-
tities, i.e. 2x3.2 mm or 2x1.6 mm discs can be set to perform similarly to high-quality DNA
from aWB reference sample, if in case the proper filter settings are applied. This validates the
use of DNA of neonatal DBSs for WES. The one most striking example illustrating the feasibil-
ity of sequencing the neonatal DNA can be inferred from the WB_ref vs WB_ref replica and
DBS_2x3.2 vs WB_ref comparisons of Pilot 2. The fact that duplicate sequencing data pro-
duced using the same high-quality DNA (e.g. the WB_ref vs WB_ref replica comparison),
scores similarly to that DNA set against wgaDNA of a neonatal DBS sample, proves the validity
of the latter. One concern of using wgaDNA of neonatal DBS samples has been if the amplifica-
tion reaction would introduce sequence errors and allele dropouts caused by the low inputs
and presumed low quality of the DNA used. However, based on the very high similarities
observed between the DBS vs WB and WB vs WB comparisons along with the very high con-
cordances overall post-filtering, we conclude that this does not seem to constitute a problem.
Methodological and Platform-Specific Considerations
Advantages, drawbacks and optimization potential exist for this methodology. Rare variant dis-
covery for instance depends heavily on large cohort sizes, which is seldom available [28]. Bio-
banks like the DNSB representing an unbiased population subset and for which the samples
can be linked to medical records may therefore be used. We suggest that the robustness of the
current methodology be further addressed using a larger cohort, potentially hundreds of sub-
jects to warrant validation in large research studies. One might also address the lower overall
exome coverage observed for neonatal DBS samples compared to WB samples in this study.
This may result from quality issues inherent to neonatal wgaDNA caused by either i) reduced
quality of the input DNA used for WGA (i.e. fragmented and/or insufficient quantities), ii)
amplification bias directed by the WGA kit used and/or iii) the fact that reduced quality of the
input DNA promotes amplification bias depending on template-specific characteristics. The
optimization could therefore be two-sided seeking to optimize the WGA reaction by testing
different amplification kits, the time of amplification, the reaction volume and/or the number
of sample replicates, or the quality of the input DNA could be improved for instance by enzy-
matic removal of surplus RNA and ssDNA to exclusively deliver dsDNA for the WGA reac-
tion. Alternatively, one could try to completely omit WGA, and use raw DNA extract for
library preparation. The DNA quantities will in this case be drastically reduced and incompati-
ble with general input recommendations; therefore, this procedure will require extensive opti-
mization. Finally, one could try to explore the potential of further downscaling the inputs of
2x1.6 mm discs for DNA extraction. This has additional prospects as Neonatal DBS are not the
only sample type which yield minute amounts of DNA for subsequent analysis. Circulating
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tumour DNA and pre-implantation screening of oocytes are examples with similar limitations.
While the approaches here could be applicable to pre-implantation screening, cancer genomes
would need separate validation. An experiment comparing amplified and unamplified matched
samples would allow exploration when the diploid assumption breaks down and polyploidy
becomes a concern.
Advantages/Limitations exist for the technology itself compared with other high-through-
put genotyping technologies. Rare variant detection by SNP microarray is for instance, delim-
ited by probe design requiring hybridization of probes of known sequence: the current settings
allow targeting only of shared variants common to a broader subset of the population [29]. In
contrast, WES applies to all variants whether common or rare in the full gene set of an individ-
ual, providing highly reliable variant calls based on great sequencing depth and coverage. Com-
pared to whole-genome sequencing (WGS), WES is more cost-effective, and because the
majority of severe disease causing variants generally sites in protein-encoding genes; focusing
only on this part (~1% of the genome) still provides a high yield of relevant information [30].
Nonetheless, WGS would no doubt stimulate a deeper and improved understanding of the
genetic variation in intergenic regions including structural and non-coding variants associated
with disease. We conclude that for exploration/identification of rare variants in regards to sam-
ple size and the ability to later on interpret the results, WES may currently be the most effective
technology.
Perspectives of the Methodology
Neonatal DBS samples may be used for WES in large cohort studies of disease, to identify the
determinants underlying common and complex genetic diseases. Options also exist for inclu-
sion of the methodology in the routine screening of neonates. Neonatal screening programmes
generally rely on the quantification of metabolic markers with associated thresholds, followed
by targeted DNA genotyping of whole-blood samples (or DBS samples) to establish the final
diagnosis [3–7, 10]. The exploitation of complete WES in neonatal screening would indeed be
faced with major political and ethical concerns relating to the use and storage safety of the data
accumulated [31]. Patients and doctors would also be supplied with lots of sequence variation
with no known function, or perhaps even with information about serious and untreatable dis-
eases, which is a big ethical dilemma. Instead, one might look at a more targeted approach,
scanning only those genes or mutations currently involved in neonatal screening programmes.
This would certainly reduce the amount of excess extra data generated to an absolute mini-
mum, and thus revoke less political and ethical objections/concerns. Overall, the outcome
would be an improved setting, allowing the confirmation of metabolic markers at the genotypic
level and vice versa. An alternative approach would be the establishment of an array-based
panel of neonatal markers, which would provide an even more focused subset of information,
however with the same possibilities as the aforementioned sequencing strategy for neonatal
screening.
Conclusions
The validation of samples by NGS typically involve the parallel sequencing of a high-quality
DNA reference to be used as a gold standard for comparison. The array-genotyping of sam-
ples (or of high-quality reference DNA), is also frequently used for comparisons to the same
samples tested on NGS platforms, providing a measure of sample reproducibility and/or of
performance [32]. Here exome-replicas of high-quality DNA, i.e. WB vs WB comparisons
were used in order to set a base-line value for evaluation of neonatal DBS samples for WES.
The concordance rates of DBS vs WB andWB vs WB comparisons were in all cases similar
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and close to 100%, confirming that wgaDNA of neonatal DBS samples performs equally to
high-quality reference DNA in WES. We found no effect of substituting 2x3.2 mm discs for
2x1.6 mm discs, allowing for a lot more flexibility in project designs relating to cohort size
and/or the number of replicas. By this end, we have processed several sample types of 22 sub-
jects allocated within three pilot studies, proving the feasibility of using neonatal DBS samples
for WES. The reproducibility of WES was found to be satisfactory independent of provider
and kit used. The integration hereof in research and/or in neonatal screening programmes
remains to be seen.
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S1 Fig. Comparisons of the DBS_2x1.6 sample type replicas with the WB_ref sample type
—concordance rates. The concordance rates were calculated by pairwise comparisons of the
DBS_2x1.6 sample type replicas with the WB_ref sample type based on the variant calls sub-
grouped according to variant type: SNPs, insertions, deletions and multiallelic calls. (A).
Graphic representation of the concordance rates before (upper panel) and after filtering (lower
panel) of the calls with replica_1 vs WB_ref, replica_2 vs WB_ref and replica_3 vs WB_ref
comparisons, respectively. (B). The exact numbers of concordance (in %) entered in table
form. Note the color-coding that has been used throughout with red, green and blue denoting
the different comparisons. Each observation represents an average of seven comparisons, cor-
responding to the number of subjects in Pilot 3.
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S1 Table. Number and percentage of variant calls by variant type before and after filtering.
The samples were assigned to variant calling on a per-pilot basis, and subsequently annotated
by variant type into SNPs, insertions, deletions and multiallelic calls, respectively. The total
number of variants and the relative percentages were determined both before and after filtering
for (A) Pilot 1, (B) Pilot 2 and (C) Pilot 3. The criteria used for filtering were: i) average sample
depth>20 and ii)minGQ_WB>30. Variant calling was with HaplotypeCaller and Unified-
Genotyper as described previously.
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S2 Table. Percentage (%) of concordance between sample types. The concordance rates were
calculated by pairwise comparisons of variant calls sub-grouped by variant type (SNPs, inser-
tions, deletions and multiallelic calls) before (Raw) and after filtering (Filt.). The sample types
compared were DBS_2x3.2 vs WB_ref in Pilot 1, DBS_2x3.2 vs WB_ref and WB_ref vs
WB_ref replica in Pilot 2 and DBS_2x3.2 vs WB_ref, DBS_2x1.6 vs WB_ref, DBS_2x3.2 vs
DBS_2x1.6 andWB_ref vs WB_WGA_ref in Pilot 3. Note that the color-coding used matches
the one used in Fig 3. Each number of concordance constitutes the average of all comparisons
for a given sample pair, corresponding to the number of subjects in the pilot: Pilot 1 = 7, Pilot
2 = 8 and Pilot 3 = 7. For comparisons using the DBS_2x1.6 sample type (see the table), each
individual replica was firstly compared to the WB_ref or DBS_2x3.2 sample types followed by
the calculation of average values hereof, which were used in the table.
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